Clinical Trials on NRAS G12R
Total 226 results
-
Elicio TherapeuticsRecruitingColorectal Cancer | Pancreatic Ductal Adenocarcinoma | KRAS G12D | KRAS G12R | NRAS G12D | NRAS G12R | KRAS G12V | KRAS G12C | KRAS G12A | KRAS G12S | KRAS G13D | NRAS G12V | NRAS G12C | NRAS G12SUnited States
-
Chinese PLA General HospitalZhejiang UniversityRecruitingSolid Tumor, Adult | KRAS G12D | EphA2 Overexpression | KRAS G12V | KRAS G12CChina
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
Revolution Medicines, Inc.RecruitingNon-Small Cell Lung Cancer, NSCLC | KRAS, NRAS, HRAS-mutated NSCLC | KRAS G12C-mutated Solid Tumors, Lung Cancer | Lung Cancer Stage IV, Advanced Solid Tumor, CancerUnited States
-
Providence Health & ServicesAvailableKRAS G12V Mutant Advanced Epithelial Cancers
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdvanced KRAS G12D Mutant Solid TumorsChina
-
Lupin Ltd.CompletedA Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid TumorsNRAS/KRAS Mutated Advanced or Metastatic Refractory Solid TumorsUnited Kingdom, Netherlands, Belgium
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingKRAS G12C Mutant Advanced Solid TumorsChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced KRAS G12D Mutant Solid TumorsChina
-
Nested Therapeutics, IncRecruitingGlioma | Melanoma | NSCLC | Oncology | Solid Tumor, Adult | MEK Mutation | RAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation | MAPK Pathway Gene MutationAustralia
-
Elicio TherapeuticsActive, not recruitingColorectal Cancer | Ovarian Cancer | Cholangiocarcinoma | Bile Duct Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Minimal Residual Disease | Gallbladder Carcinoma | KRAS G12D | KRAS G12R | NRAS G12D | NRAS G12RUnited States
-
BeBetter Med IncXiangya Hospital of Central South UniversityRecruitingAdvanced or Metastatic Solid Tumor | KRAS G12C MutationChina
-
University Health Network, TorontoBayer; AstraZeneca; Amgen; Applied Health Research Centre; Takeda Canada, Inc.; Programs...RecruitingCancer | Malignancies Multiple | Malignant Solid Tumor | Cancer, Therapy-Related | Molecular Sequence Variation | Genetic Alteration | Gene Fusion | Receptor Tyrosine Kinase Gene Mutation | RTK Family Gene Mutation | Ras (Kras or Nras) Gene MutationCanada
-
Frontier Medicines CorporationRecruitingColorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Unresectable Solid Tumor | KRAS G12C | Advanced Solid Tumors With KRAS G12C MutationsUnited States
-
University Health Network, TorontoCompletedColorectal Cancer | KRAS Wildtype | NRAS Wildtype | BRAF WildtypeCanada
-
Cardiff OncologyPfizerRecruitingMetastatic Colorectal Cancer | CRC | KRAS/NRAS MutationUnited States
-
University of UtahTerminatedKRAS and NRAS Wild-type Colorectal CancerUnited States
-
Affini-T Therapeutics, Inc.RecruitingColorectal Cancer | Non-Small Cell Lung Cancer | Solid Tumor | Pancreatic Ductal Adenocarcinoma | KRAS G12VUnited States
-
N.N. Petrov National Medical Research Center of...RecruitingMelanoma | Lung Cancer | Pancreas Cancer | Refractory Cancer | Colorectal Cancer Recurrent | RAS Mutation | Ras (Kras or Nras) Gene MutationRussian Federation
-
Murdoch Childrens Research InstituteRoyal Children's Hospital; Peter MacCallum Cancer Centre, AustraliaNot yet recruitingArteriovenous Malformations | Vascular Malformations | MAP2K1 Gene Mutation | PIK3CA-related Overgrowth Spectrum | Vascular Anomalies | Lymphangioma | Lymphatic Malformation | KRAS G12D | Venous Malformation | Vascular Anomaly | KRAS G12C | PI3K Gene Mutation | Slow-Flow Vascular Malformation | Fast-Flow Vascular... and other conditionsAustralia
-
Henan Cancer HospitalCompletedWild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer
-
AmgenActive, not recruitingKRAS p, G12c Mutated /Advanced Metastatic NSCLCFinland, United States, Canada, Belgium, Spain, Korea, Republic of, Netherlands, United Kingdom, Australia, Denmark, Hungary, Sweden, Taiwan, Greece, Russian Federation, Switzerland, France, Italy, Japan, Poland, Brazil, Germany, Po...
-
OnKure, Inc.Active, not recruitingMelanoma | NRAS Gene Mutation | RAS MutationUnited States
-
Karen-Lise Garm SpindlerCompletedColorectal Cancer Metastatic | KRAS Gene Mutation | Circulating Tumor DNA | BRAF Gene Mutation | NRAS Gene Mutation | Epidermal Growth Factor Receptor InhibitorDenmark
-
Ryan Gentzler, MDMirati Therapeutics Inc.; University of VirginiaNot yet recruitingAdagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain MetastasesNSCLC | Non Small Cell Lung Cancer | KRAS G12C
-
ETOP IBCSG Partners FoundationAmgen; Eisai Inc.WithdrawnMetastatic Non Small Cell Lung Cancer | KRAS G12CSpain, Switzerland, Austria, Germany
-
xCuresCancer CommonsAvailableExpanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesMelanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditionsUnited States
-
NYU Langone HealthWithdrawnAdvanced Non-small Cell Lung Cancer With KRAS G12C MutationUnited States
-
Black Diamond Therapeutics, Inc.RecruitingMelanoma | Colorectal Cancer | NSCLC | Solid Tumor | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Non-small Cell Lung Cancer | Histiocytosis | Melanoma (Skin) | Recurrent Melanoma | Thyroid Carcinoma | Thyroid Cancer | Brain Metastases | Recurrent Histiocytic and Dendritic... and other conditionsUnited States
-
Cairo UniversityRecruiting
-
Shanghai Zhongshan HospitalRecruiting
-
Tanta UniversityCompleted
-
Minia UniversityNot yet recruiting
-
Ataturk UniversityNot yet recruiting
-
University of PennsylvaniaCompleted
-
Dr. Soetomo General HospitalCompleted
-
NYU Langone HealthRecruitingAdvanced Non-small Cell Lung Cancer With KRAS G12C MutationUnited States
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
-
King Saud Medical CityActive, not recruiting
-
Addario Lung Cancer Medical InstituteRecruiting
-
University of ThessalyRecruiting
-
D3 Bio (Wuxi) Co., LtdRecruitingKRAS P.G12CAustralia, Korea, Republic of, China, United States, Hong Kong
-
Cliniques universitaires Saint-Luc- Université...Completed
-
Daping Hospital and the Research Institute of Surgery...UnknownInfant, Newborn, NRDSChina
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Eli Lilly and Company; Genentech, Inc.; Kazia... and other collaboratorsRecruitingMetastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain | NTRK Family Gene Mutation | CDK Gene Mutation | PI3K Gene Mutation | ROS1 Gene Mutation | KRAS G12C MutationUnited States
-
Boehringer IngelheimCompletedSolid Tumors, KRAS MutationJapan
-
Zeynep Kamil Maternity and Pediatric Research and...Enrolling by invitationCesarean Section Complications | ERASTurkey
-
Boehringer IngelheimActive, not recruitingSolid Tumors, KRAS MutationSpain, United Kingdom, United States, Belgium
-
Dr.Laurent MineurMerck Serono International SA; BESPIM, CHU Nîmes (data analysis)Unknown